Regeneron Pharmaceuticals (REGN) Stock Forecast & Price Target

Regeneron Pharmaceuticals
Bull Case

Here are some ways that investors could benefit from investing in Regeneron Pharmaceuticals, Inc.:

• Regeneron Pharmaceuticals, Inc. recently reported positive 84-week data for its newly approved drug Pasatru, which demonstrated zero new heterotopic ossification lesions in patients with fibrodysplasia ossificans progressiva, a rare disease, providing strong evidence of long-term efficacy and supporting the commercial viability of this first-in-class treatment.
• The company significantly outperformed market expectations in its most recent quarterly earnings report, delivering earnings per share of $14.29 against a consensus estimate of $10.16 and generating revenue of $4.29 billion, which exceeded the projected $3.82 billion, indicating robust financial health and strong demand for its therapeutic portfolio.
• With the current stock price at $778.36, Regeneron Pharmaceuticals, Inc. trades at a price-to-earnings ratio of 19.24, which is notably lower than the median multiple of the S&P 500, suggesting that the stock may be undervalued relative to broader market peers despite its strong growth trajectory and recent earnings beats.
• Analyst sentiment remains positive with a consensus rating of Moderate Buy and an average price target of $834.24, reflecting institutional confidence in the company's future performance, particularly as firms like UBS and Jefferies have recently raised their targets or initiated buy ratings based on the potential of key products like Dupixent.
• Regeneron Pharmaceuticals, Inc. maintains a low beta of 0.16, indicating that its stock price is significantly less volatile than the overall market, which can provide a defensive characteristic for investors seeking stability in their biotechnology holdings during periods of market uncertainty.